by Mayank Shukla, MD
Asthma remains one of the most common chronic diseases affecting children worldwide. Although inhaled corticosteroids and bronchodilators have dramatically improved asthma control, they primarily suppress airway inflammation rather than modifying the underlying allergic immune response responsible for disease progression. Since approximately 70–90% of childhood asthma is associated with allergic sensitization, management strategies directed toward the allergic basis of disease deserve greater emphasis. Allergen immunotherapy, administered either by subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT), represents the only treatment capable of modifying the natural course of allergic disease. This article discusses the rationale for incorporating immunotherapy earlier into the routine management of appropriately selected children with allergic asthma and presents clinical observations from more than 25 years of practice. By rethinking the management of allergic asthma in children, we may open the door to more meaningful health care benefits through developmental years and beyond.
Introduction to Rethinking the Management of Allergic Asthma in Children
Asthma is a chronic inflammatory disorder characterized by variable airflow obstruction, airway hyperresponsiveness, and recurrent respiratory symptoms including cough, wheezing, chest tightness, and shortness of breath. In children, allergic sensitization plays a dominant role in disease pathogenesis, with studies demonstrating that approximately 70–90% of pediatric asthma is associated with environmental allergen sensitization.
Exposure to allergens, including dust mites, tree pollen, grasses, weeds, molds, and animal dander, initiates an IgE-mediated inflammatory cascade that affects the entire respiratory tract. Viral respiratory infections frequently amplify this inflammatory response, resulting in recurrent asthma exacerbations, emergency department visits, hospitalization, school absenteeism, and impaired quality of life.
Current Therapeutic Paradigm
Current international guidelines recommend inhaled corticosteroids as the cornerstone of long-term asthma management. These medications effectively suppress airway inflammation and reduce exacerbations. However, corticosteroids do not alter the underlying allergic immune response responsible for disease recurrence.
Repeated or prolonged corticosteroid exposure, particularly frequent courses of systemic corticosteroids, has been associated with clinically important adverse effects including:
- Impaired growth
- Adrenal suppression
- Osteoporosis
- Cataracts
- Hypertension
- Diabetes
- Behavioral changes
- Increased susceptibility to infection
- Reduced bone mineral density
These concerns emphasize the importance of identifying steroid-sparing therapeutic strategies whenever possible.
Immunotherapy: Treating the Cause Rather Than the Symptoms
Unlike pharmacologic therapy, allergen immunotherapy addresses the underlying immunologic mechanism responsible for allergic asthma. Through repeated exposure to carefully standardized allergen extracts, immunotherapy induces immune tolerance, reducing IgE-mediated inflammation while promoting long-term immunologic modification.
Treatment may be delivered as:
- Subcutaneous immunotherapy (SCIT)
- Sublingual immunotherapy (SLIT)
Both modalities have demonstrated reductions in allergy symptoms, asthma symptoms, medication requirements, and improvements in quality of life in appropriately selected patients. Current GINA guidelines recognize allergen immunotherapy as the only treatment with disease-modifying potential for allergic respiratory disease.
A Different Clinical Perspective
Historically, many physicians have been reluctant to initiate immunotherapy in patients with severe asthma because of concerns regarding systemic allergic reactions or worsening asthma.
Current guidelines recommend that immunotherapy should only be initiated after asthma has been brought under good clinical control and should be administered by experienced clinicians in settings equipped to manage anaphylaxis.
Over the past 25 years, our clinical practice has incorporated allergen immunotherapy into the management of carefully selected children with moderate-to-severe allergic asthma after stabilization of asthma control. With careful patient selection, individualized allergen formulation, and close monitoring, our experience suggests that immunotherapy can substantially reduce asthma burden while decreasing dependence on inhaled and systemic corticosteroids.
These observations warrant formal prospective investigation and may help expand understanding of the role of immunotherapy in patients traditionally considered difficult to treat.
Long-Term Clinical Benefits
In our experience, patients completing three to five years of immunotherapy frequently demonstrate:
- Fewer asthma exacerbations
- Reduced need for inhaled corticosteroids
- Reduced need for oral corticosteroids
- Improved pulmonary function
- Reduced emergency department visits
- Reduced hospitalization
- Fewer missed school days
- Improved exercise tolerance
- Better quality of life for children and families
Although randomized controlled trials report more modest average treatment effects than individual clinical experiences, published evidence consistently supports reductions in asthma symptoms and medication requirements among appropriately selected patients receiving immunotherapy.
Future Directions
The future of asthma management should extend beyond symptom suppression. Precision medicine requires identifying the biologic drivers of disease and targeting those mechanisms early in the disease course.
For children with documented allergic sensitization and adequately controlled asthma, allergen immunotherapy should be considered as a disease-modifying treatment alongside guideline-directed pharmacotherapy. Earlier implementation may reduce long-term medication exposure, improve disease control, and potentially alter the natural history of allergic respiratory disease.
Further multicenter prospective studies are needed to define which patient populations derive the greatest benefit, determine optimal treatment protocols, and evaluate long-term clinical outcomes.
Conclusion
Asthma treatment should focus not only on controlling symptoms but also on modifying the disease process itself. Allergen immunotherapy represents an important therapeutic option capable of targeting the underlying allergic mechanisms responsible for many cases of pediatric asthma.
After more than two decades of clinical experience, we believe immunotherapy deserves greater consideration as an integral component of comprehensive asthma care for appropriately selected children. Continued research will further clarify its role and help optimize patient selection and treatment outcomes.
References
Global Initiative for Asthma. Global strategy for asthma prevention and management—2025. Updated November 2025.
